Accuray Incorporated, manufacturer of the CyberKnife® Robotic Radiosurgery System, recently presented new data that demonstrates the CyberKnife System’s effectiveness in treating central nervous system (CNS) tumors.
The data was presented at the 2025 Radiosurgery Society (RSS) Scientific Meeting, held in Tucson, Arizona. The RSS is an international, medical professional, non-profit society consisting of physicians, physicists, and healthcare professionals dedicated to advancing the education, science, and clinical practice of stereotactic radiosurgery, stereotactic body radiation therapy, and advancing therapies.
Central nervous system (CNS) tumors are growths that develop in the brain and spinal cord. These tumors can be either benign (non-cancerous) or malignant (cancerous). They can be primary, meaning they originate in the CNS, or secondary, meaning they spread from another part of the body.
CNS tumors encompass a wide variety of types, including gliomas, ependymomas, meningiomas, craniopharyngiomas, and many more. They vary in their characteristics, growth rates, and impact on brain function. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the U.S.
At Austin CyberKnife, we treat CNS tumors with radiation therapy using the CyberKnife® Robotic Radiosurgery System. The CyberKnife System’s innovative technology delivers robotic-precision, high-dose radiation therapy, minimizing damage to surrounding healthy tissue. The safe and effective treatments are quick, non-invasive, and have little to no side effects or recovery time.
To learn more about treating CNS tumors with CyberKnife technology, please contact the team at Austin CyberKnife today.